GS-621763

remdesivir analogue; deuterated HBr salt (VV116/JT001) used to treat COVID-19

Also Known As:

((2R,3R,4R,5R)-5-(4-amino-5-deuterio-pyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)tetrahydrofuran-2-yl)methyl 2-methylpropanoate hydrobromide; ((2R,3R,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)tetrahydrofuran-2-yl)methyl 2-methylpropanoate; (2R,3R,4R,5R)-2-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2-cyano-5-((isobutyryloxy)methyl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate); GS 621763; GS-441524 prodrug; GS621763; JT-001; JT001; VV-116; VV116

Networked: 20 relevant articles (4 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wang, Zhen: 2 articles (12/2022 - 12/2022)
2.	Babusis, Darius: 2 articles (01/2022 - 09/2021)
3.	Bannister, Roy: 2 articles (01/2022 - 09/2021)
4.	Baric, Ralph S: 2 articles (01/2022 - 09/2021)
5.	Barrett, Kimberly T: 2 articles (01/2022 - 09/2021)
6.	Bilello, John P: 2 articles (01/2022 - 09/2021)
7.	Bleier, Blake J: 2 articles (01/2022 - 09/2021)
8.	Brown, Ariane J: 2 articles (01/2022 - 09/2021)
9.	Chun, Kwon: 2 articles (01/2022 - 09/2021)
10.	Cihlar, Tomas: 2 articles (01/2022 - 09/2021)

Related Diseases

1.	COVID-19 09/17/2021 - "Therapeutic GS-621763 significantly reduced viral load, lung pathology, and improved pulmonary function in COVID-19 mouse model. " 01/01/2022 - "Therapeutic GS-621763 administration reduced viral load and lung pathology; treatment also improved pulmonary function in COVID-19 mouse model. " 11/22/2023 - "Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study." 11/22/2023 - "Among patients with mild-to-moderate COVID-19, VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns. " 04/01/2023 - "VV116 as a potential treatment for COVID-19."
2.	Cryopyrin-Associated Periodic Syndromes 01/01/2023 - "Orally administered JT001 was effective in reducing hepatic inflammation in three different murine models, including the Nlrp3A350V /+CreT model of Muckle-Wells syndrome (MWS), a diet-induced obesity NASH model, and a choline-deficient diet-induced NASH model. "
3.	Obesity 01/01/2023 - "Orally administered JT001 was effective in reducing hepatic inflammation in three different murine models, including the Nlrp3A350V /+CreT model of Muckle-Wells syndrome (MWS), a diet-induced obesity NASH model, and a choline-deficient diet-induced NASH model. "
4.	Inflammation (Inflammations) 01/01/2023 - "Our findings demonstrate that blockade of NLRP3 attenuates hepatic inflammation and fibrosis and support the use of JT001 to investigate the role of NLRP3 in other inflammatory disease models. " 01/01/2023 - "Orally administered JT001 was effective in reducing hepatic inflammation in three different murine models, including the Nlrp3A350V /+CreT model of Muckle-Wells syndrome (MWS), a diet-induced obesity NASH model, and a choline-deficient diet-induced NASH model. "
5.	Critical Illness (Critically Ill) 01/01/2020 - "A new recommendation was made against the antiviral agent VV116 for patients with non-severe and with severe or critical illness outside of randomised clinical trials based on one RCT comparing the drug with nirmatrelvir/ritonavir. "

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Choline (Choline Chloride)
3.	nirmatrelvir and ritonavir drug combination
4.	molnupiravir
5.	azvudine
6.	GS-621763
7.	GS-441524
8.	Prodrugs
9.	Nucleotides
10.	bucillamine (SA 96)

Related Therapies and Procedures

1.	Oral Administration